1006377-36-1Relevant articles and documents
COMPOUNDS THAT INHIBIT NFκB ACTIVITY
-
Page/Page column 5; 34-35, (2010/05/14)
The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment o
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation
Xie, Yuli,Deng, ShiXian,Thomas, Craig J.,Liu, Yidong,Zhang, Ya-Qin,Rinderspacher, Alison,Huang, Wenwei,Gong, Gangli,Wyler, Michael,Cayanis, Efithia,Aulner, Nathalie,Toebben, Udo,Chung, Caty,Pampou, Sergey,Southall, Noel,Vidovic, Dusica,Schuerer, Stephan,Branden, Lars,Davis, R. Eric,Staudt, Louis M.,Inglese, James,Austin, Christopher P.,Landry, Donald W.,Smith, Deborah H.,Auld, Douglas S.
, p. 329 - 335 (2008/09/16)
We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NFκB pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in bot
